Committee on Energy and Commerce
U.S. House of Representatives

Witness Disclosure Requirement – "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Ronald T. Piervincenzi		
2. Your Title: Chief Executive Officer		
3. The Entity(ies) You are Representing: The United States Pharmacopeial Convention, Inc. (USP)		
4. Are you testifying on behalf of the Federal, or a State or local government entity? (If "Yes," skip Item 5 and Item 6.)	**Yes**	**No** X
5. Grants, Contracts, and Payments **a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.** **b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.**		
6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?	**Yes** **X**	**No**
7. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____ **Date:** **June 9, 2025**

INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

In General. The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

> (B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include—(i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing. (C) The disclosure referred to in subdivision (B)(ii) shall include—(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

Please complete the form in accordance with these directions.

1. ***Name (Item 1 on the form).*** Please provide the name of the witness.

2. ***Title (Item 2 on the form).*** Please provide the title of the witness.

3. ***Entity(ies) (Item 3 on the form).*** Please identify the entity(ies) on whose behalf the witness is testifying.

4. ***Governmental Entity (Item 4).*** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental entities. If you answer "Yes" to Item 4, please skip Item 5.a, Item 5.b, and Item 6.

5. ***Grants and Contracts***

   a. ***(Item 5.a.).*** Please list any Federal grants or contracts that you or the entity(ies) you represent have received on or after January 1, 2023. For each such grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. Only grants, contracts, or payments related to the hearing must be listed.

   b. ***(Item 5.b.).*** Please list any contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2023. For each such contract or payment related to the subject matter of the hearing, please include the amount and country of origin. Only grants, contracts, or payments related to the hearing must be listed.

6. ***Fiduciary Capacity (Item 6).*** Please check the box indicating whether or not the witness is a fiduciary of **any** organization or entity with an interest in the subject matter of the hearing. This includes, but is not limited to, serving as a director, officer, advisor, or resident agent of an entity with an interest in the hearing.

7. ***Curriculum Vitae (Item 7).*** Please attach your CV to your completed disclosure form.

8. ***Submission.*** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee's rules, copies of a written statement of your proposed testimony must be submitted before the hearing commencements. To the greatest extent practicable, please also provide a copy in electronic format according to the accompanying Electronic Format Guidelines.

Question 5 Grants and Contracts

(Item 5.a.). Please list any Federal grants or contracts that you or the entity(ies) you represent have received on or after January 1, 2023. For each such grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. Only grants, contracts, or payments related to the hearing must be listed.

Award/Project Title/Description	Award Ceiling/ Amount	Originating Funding Source (if applicable)	Client	Start Date Period of Performance	End Date Period of Performance	Award Type
Foundry for American Biotechnology (NextFab) OTAA Lower Tier Agreement 23-01	$419,936	DHHS/ASPR	ARMI	6/19/2023	12/31/2024	OTAA Subaward
Texas A&M University (TAMU) mRNA Course Development & License Agreement (license term 3 years or 09/25/2023 - 09/25/2026)	$13,126	DHHS/BARDA	TAMU	7/17/2023	7/31/2023 and 9/25/2026	Purchase Order
Phlow Government Work Order (GWO) No. 5	$416,706	ASPR/BARDA	Phlow Corp.	5/22/2024	1/31/2025	Work Order
Phlow Government Work Order (GWO) No. 6	$418,239	ASPR/BARDA	Phlow Corp.	5/22/2024	1/31/2025	Work Order
Phlow Government Work Order (GWO) No. 7	$316,885	ASPR/BARDA	Phlow Corp.	5/22/2024	1/31/2025	Work Order
NSF Engines: Develop governance practices amongst the consortium in order to accelerate the growth and long-term sustainability of an advanced pharmaceutical manufacturing (APM) industry in the historically distressed Richmond+Petersburg Region.	$95,267	NSF	Activation Capital	6/10/2024	2/28/2026	Subagreement
Phlow Government Work Order (GWO) No. 8	$380,800	ASPR/BARDA via DoD JPEO	Phlow Corp.	9/9/2024	1/31/2025	Work Order
Kyrgyzstan Cure TB 2 Project	$2,228,206	USAID	JSI	9/23/2024	8/17/2029	Subagreement
U.S. White House Executive Office of the President (EOP) Office of Pandemic Preparedness (OPPR)	$149,914	EOP	OPPR	9/30/2024	3/29/2025	Purchase Order Contract
Kenya Integrated Pharmaceutical and Supply Chain Technical Assistance Project Task Order	$1,206,264	USAID	DAI Global	10/24/2024	Terminated Feb 27, 2025	Subcontract
Wheat-based Highefficiency Enzyme and API Technology (WHEAT) Project	$3,500,000	ARPA-H	Ginkgo Bioworks, Inc.	3/28/2025	3/27/2027	OTAA Subcontract

Ronald T. Piervincenzi, Ph.D.
[redacted]

PROFESSIONAL EXPERIENCE

United States Pharmacopeial Convention, Inc. **Rockville, MD**
Chief Executive Officer **Feb. 2014-present**

- Provides strategic leadership for USP at the direction of its Board of Trustees of which the CEO is a member (ex officio).
- Leads a staff of over 1,300 worldwide including Rockville, Maryland, and major laboratory sites in India, China, Ghana and Brazil
- Responsible for oversight and leadership of USP's Global Public Health initiatives across over 30 countries including sites in Ethiopia, Indonesia, Kenya, Nepal, Bangladesh, Pakistan and Nigeria.
- Ensures USP maintains its reputation (in place since its founding in 1820) and impact through adherence to mission and values
- Manages a set of businesses resulting in revenue of over $340M per year
- Served as interim Chair of the Council of Experts, USP's scientific standards-setting body which consists of 24 Expert Committees and over 800 standards-setting experts

Biogen Idec, Inc. **Cambridge, MA**
VP, Development Sciences, Business Strategy **July 2013-Jan. 2014**

- Designed and launched Biogen's "Value-Based Medicine" function

McKinsey & Company, Inc. **Summit, NJ**
Principal (Partner) **Oct. 2000-May 2013**

- ***Selected non-client leadership roles within McKinsey:***
  - Partner leader of McKinsey's Pharmaceutical and Medical Products Research and Knowledge Network. Managed 40+ staff located in New Jersey, London, Brussels, and India
  - Founder and leader of McKinsey's Global Medical Service Line encompassing Medical Affairs, Safety, R&D Quality; leader within Global Pharmaceutical and Medical Products Practice
  - Overall leader of McKinsey's NJ Office *pro bono* efforts including Newark education reform (formation of *Foundation for Newark's Future*) and launch of *Newark Mentorship Movement*
- ***Business building/strategy experience:***
  - Pharmaceutical/Biotech Franchise/business unit strategy – Led engagements to set strategic and financial goals, Medical Device Growth Strategies – Led engagements acquisition/business development investment to growth areas
  - Pharmaceutical Marketing and Sales – Led engagements on sales force deployment/sizing, product marketing strategies, and overall therapeutic area/franchise strategies
- ***Pharmaceutical and Biotech research and development (R&D) experience:***
  - Medical, Safety and Quality – Overall led or advised on nearly all of McKinsey's global engagements over past 6+ years globally. Clinical Development – Led engagements to diagnose and improve clinical operations
  - Research and Early Development – Led early stage research strategy engagements Regulatory – Led engagements for both industry (i.e., Regulatory Affairs) and in Public Sector (i.e., FDA)
- ***Business development experience:***
  - M&A/Licensing analyses – Led several engagements identifying and assessing M&A opportunities

OTHER LEADERSHIP ROLES

MENTOR Newark (MN) **Newark, NJ**
Co-founder and Chairman of the Board **Dec 2011-present**

- Partnered with Mayor Cory Booker to found MN (formerly Newark Mentoring Movement), with mission to make mentoring easier and more accessible and more effective throughout the City of Newark – working to quadruple the number of Newark youth being mentored within 5 years

EDUCATION

Duke University **Durham, NC**
M.S. and Ph.D., Biomedical Engineering (Whitaker Graduate Fellow) **Sep 1993-July 2000**

- Ph.D. (May 1996-Jul 2000): *Novel techniques for protein conjugation and affinity modulation using genetic circular permutation*; Molecular switches and drug delivery technologies
- M.S. (Sep 1993-May 1996) with Thesis: *Genetic engineering of a single-chain antibody fragment for immobilization in an optical biosensor*

Hofstra University **Hempstead, NY**
B.E., Engineering Science; Mathematics minor **Sep 1989-May 1993**

- GPA: 3.8; Graduated *summa cum laude* with *engineering high honors*

PUBLICATIONS

- K Trabbic-Carlson, DE Meyer, L Liu, R Piervincenzi, N Nath, T LaBean, and A Chilkoti. *Effect of protein fusion on the transition temperature of an environmentally responsive elastin-like polypeptide*, Protein Engineering, vol. 17, January, 2004
- RT Piervincenzi and A Chilkoti. *The effects of genetic circular permutation near the active site on the activity and stability of an enzyme inhibitor,* Biomol. Engr., 15 August, 2003
- RT Piervincenzi, WM Reichert, and HW Hellinga. *Genetic engineering of a single-chain antibody fragment for surface immobilization in an optical biosensor,* Biosensors and Bioelectronics, 13, 1998
- SY Rabbany, RT Piervincenzi, and FS Ligler. *Dissociation rate kinetics in a solid-phase flow immunoassay,* Analytical Letters, 31, 1998
- SY Rabbany, RT Piervincenzi, and FS Ligler. *Assessment of heterogeneity in antibody-antigen displacement reactions,* Analytical Chemistry, 69, 1997